The Shift Toward Western Pharmaceutical Manufacturing

By James Grabowski, Ph.D., Vice President, Business Unit Operations - API, Curia

The COVID-19 pandemic has starkly underscored the global interdependency of pharmaceutical supply chains, shedding light on vulnerabilities and prompting renewed conversations about reshoring production. According to the U.S. Food and Drug Administration (FDA), a significant 72% of facilities manufacturing Active Pharmaceutical Ingredients (APIs) for American drugs are located overseas, with 13% of these in China.

In our comprehensive white paper, we delve into the complexities of securing and de-risking pharmaceutical supply chains in light of these findings. Furthermore, we unveil Curia's proactive strategies and measures aimed at ensuring the uninterrupted production of critically needed drugs, even in the face of unprecedented disruptions. Gain valuable insights into navigating the evolving landscape of pharmaceutical manufacturing and safeguarding the availability of essential medications by downloading our white paper below.